Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VP Venture Partners is a private venture capital firm located in Zurich, Switzerland. Founded by Dr. Valentin Piëch, the firm is committed to enhancing the European life science ecosystem by supporting startups from early stage to exit. The firm focuses on building, coaching, and financing innovative companies in the life sciences sector.
Currently, VP Venture Partners manages a portfolio of 9 companies, primarily in the early stages of development. The firm emphasizes deep tech ventures that address unmet medical needs, particularly in the fields of biotech, healthcare, and digital health. Their approach includes providing hands-on support and operational guidance to help startups navigate challenges and accelerate their path to market.
VP Venture Partners operates with a clear mission to impact the European life science landscape positively. The firm’s team includes experienced professionals with backgrounds in both venture capital and life sciences, ensuring that they can offer valuable insights and resources to their portfolio companies.
VP Venture Partners specializes in investing in early-stage life sciences companies, particularly at the pre-seed and seed stages. Their investment strategy is centered around human life science ventures, including medical devices, digital health, and diagnostics. Notably, the firm excludes investments in therapeutics and drug development, allowing them to concentrate on areas with high potential for patient impact.
The firm seeks dedicated teams that are passionate about bringing innovative products to market. VP Venture Partners provides hands-on support, including operational and strategic guidance, and can take interim C-level positions within portfolio companies. This operational involvement is designed to help startups overcome challenges and achieve their growth objectives.
VP Venture Partners targets high unmet medical needs, focusing on deep tech ventures that can significantly impact patient care. Their investment philosophy emphasizes collaboration with founders who share a commitment to innovation and excellence in the life sciences sector.
VP Venture Partners has a diverse portfolio of 9 companies, each contributing to advancements in life sciences:
Dr. Valentin Piëch: Founder and Managing Partner. Dr. Piëch has extensive experience in venture capital and life sciences, focusing on early-stage investments in Europe.
Vendy Zgraggen: Managing Partner. Zgraggen brings a wealth of knowledge in operational management and strategic development within the life sciences sector.
Dr. Annick Bay: Investment Manager. Dr. Bay has a strong background in biomedical research and investment analysis, contributing to the firm's investment decisions.
Dr. Ruth Ketley: Associate. Dr. Ketley specializes in evaluating early-stage life sciences ventures and has a background in clinical research.
Dr. Julia Flötotto: Venture Partner. Dr. Flötotto has experience in both venture capital and life sciences, focusing on deep tech investments.
Dr. Hans Maria Heÿn: Venture Partner. Dr. Heÿn brings expertise in medical technology and innovation, enhancing the firm's investment strategy.
To pitch VP Venture Partners, startups should visit their website at [vpventurepartners.com](https://vpventurepartners.com) for specific guidelines. A well-structured pitch deck should include details about the team, product, market opportunity, and financial projections.
Startups are encouraged to provide a clear narrative that outlines their vision and the problem they aim to solve. While the firm does not specify a response time, founders should be prepared for a thorough evaluation process.
As of March 2023, VP Venture Partners continues to expand its portfolio in the life sciences sector, focusing on early-stage investments. The firm has recently added several innovative companies to its portfolio, enhancing its commitment to addressing unmet medical needs in Europe.
In addition, VP Venture Partners has been actively involved in supporting its existing portfolio companies through operational guidance and strategic mentorship, helping them navigate the challenges of early-stage development.
What are the investment criteria for VP Venture Partners?
VP Venture Partners invests in early-stage life sciences companies, specifically at the pre-seed and seed stages. They focus on human life science ventures, including medical devices, digital health, and diagnostics, while excluding therapeutics and drug development.
How can startups apply or pitch to VP Venture Partners?
Startups interested in pitching to VP Venture Partners can visit their website at [vpventurepartners.com](https://vpventurepartners.com) for more information on the application process.
What makes VP Venture Partners different from other venture capital firms?
VP Venture Partners distinguishes itself through its hands-on support model, providing operational and strategic guidance to portfolio companies. They can also take interim C-level positions to help startups navigate challenges effectively.
What is the geographic scope of VP Venture Partners?
The firm primarily invests in early-stage life sciences companies located in Europe, focusing on ventures that address unmet medical needs.
What is the typical check size for investments made by VP Venture Partners?
While specific check sizes are not disclosed, VP Venture Partners focuses on early-stage investments, which typically range from pre-seed to seed funding levels.
What kind of post-investment involvement can portfolio companies expect?
VP Venture Partners provides hands-on support, including operational and strategic guidance, and can take interim C-level positions to assist portfolio companies in achieving their growth objectives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.